Meta-Analysis: No Benefit For Cardiac Resynch In Patients With Narrow QRS Interval
This article was originally published in The Gray Sheet
Executive SummaryCardiac resynchronization therapy may not benefit up to 40% of heart failure patients who currently receive CRT devices and whose “QRS duration” on an electrocardiogram is below a certain threshold, according to a meta-analysis published June 13.
You may also be interested in...
The trial shows that cardiac-resynchronization therapy does not reduce mortality or hospitalizations in heart failure patients with a QRS duration shorter than 130 milliseconds on an electrocardiogram. The finding essentially affirms current guidelines, but it does not support off-label practice by some cardiologists who had hoped CRT could be useful in a broader patient population.